Overview

Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer

Status:
Recruiting

Trial end date:
2023-12-20

Target enrollment:

Participant gender:

Summary

This study evaluated the effectiveness and safety of Camrelizumab combination with SBRT and concurrent chemotherapy treated stage IV oligometastatic non-small cell lung cancer

Phase:

Phase 2

Details

Lead Sponsor:

Sichuan Cancer Hospital and Research Institute